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HFE polymorphisms frequency 
HFE_H63D and C282Y 
genotype frequency in the CHC 
studied population is 
summarized in Table 5. 
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Chronic hepatitis C (CHC) is often associated with alterations in iron and lipid metabolisms, which may affect the long-term prognosis and the response to antiviral 
treatment (1,2). Some studies have suggested that the occurrence of HFE mutations may contribute to modulate these metabolisms in CHC (3,4).  In this study, the 
prevalence of two common HFE mutations (C282Y and H63D) was determined in a group of Portuguese CHC patients and the findings were correlated with their 
clinical, histological and virological features. 
•  Clinical parameters were measured by standard techniques: AST, ALT, GGT, lipid profile 
(LDL, HDL, total cholesterol  and triglycerides), iron, ferritin, transferrin and saturation, 
insulin, glucose, HOMA- IR and peptide-C .  
•  82 patients were treated with SOC (Pegynterferon + Ribavirin).  
•  HCV-RNA was determined by PCR and genotype by Inno-Lipa.  
•  Liver steatosis, fibrosis stage and degree of inflammation (grading) were assessed by  
liver biopsy (Peter Scheuer  score). 
•   HFE polymorphisms, H63D and C282Y, were analyzed by PCR-RFLP.  
•   Antioxidant potencial (tGSH/GSSG Ratio) was evaluated by spectrofluorimetry. 
•    Statistical analysis was performed by SPSS 19.0 (level of significance p<0.05). Clinical 
data results were corrected for age and BMI using a General Linear Model – Univariate. 
Population 
•   One hundred and eighty three CHC patients were enrolled in this study.  
•   Population clinical parameters, liver histology, virus genotype and type of anti-viral response 
are described in Tables 1-4. 
•   Patients exclusion criteria: other chronic liver diseases, alcohol ingestion >40g/day, HIV 
infection, metabolic and autoimmune diseases.  
 
Table 3. Virus Genotype  
Type Subtype N (%) 
1 
1a 47 (27.5) 
1b 64 (37.4) 
2 2,2a, 2c, 2a+2c 4 (2.3) 
3 3a 39 (22.8) 
4 4, 4c, 4d, 4a+4c+4d, 4c+4d 16 (9.4) 
other 1a+3a 1 (0.6) 
Total 171 
Table 2. Liver Histology  
Parameter Stage N (%) Total (N) 
Fibrosis 
(staging) 
F1/2 90 (76.9) 
117 
F3/4 27 (23.1) 
Steatosis 
With 72 (75.0) 
96 
Without 24 (25.0) 
Steatosis Grade 
Mild (1+2) 52 (72.2) 
72 
Moderate or severe (3+4) 20 (27.8) 
Inflammation 
(grading) 
Mild (1-3) 25 (22.3) 
112 Moderate (4-6) 87 (77.7) 
Severe (>6) (0) 
Table 1: Population Clinical Parameters   
Clinical parameters 
(normal distribution) 
Mean Std Deviation 
Clinical parameters 
(non normal distribution) 
Median Min. Max. 
Age (years) 45.84 11.46 HCV-RNA (UI/mL) 267857 0 1.5E6 
BMI (Kg/m2) 25.45 3.96 Triglycerides (mmol/L) 1.1 0.3 13.6 
Total Cholesterol (mmol/L) 4.43 1.10 
Alcaline Phosphatase  
(µg/dL) 
66 27 395 
HDL (mmol/L)/ 
LDL (mmol/L) 
1.34/ 
2.49 
0.53/ 
0.97 
AST / ALT (UI/L) 
47/ 
75 
16/ 
16 
654/ 
505 
Transferrin (µg/dL)/  
Sat (%) 
303.50/ 
44.41 
74.91/ 
20.66 
Gama GT (UI/L) 45 10 1139 
Haptoglobin (mg/dL) 92.63 39.48 Ferritin (ng/mL) 178 9.4 2479 
Ceruloplasmin (mg/dL) 37.44 12.15 Insulin (μU/mL) 9.9 1.6 81.2 
tGSH ( g/mL) 21.34 10.49 Glycemia (mg/dL) 87 61 203 
GSSG( g/mL) 3.73 1.82 
HOMA  
(μU/mL xmg/dL) 
2.1 0.3 19.6 
tGSH/GSSG Ratio 6.24 2.31 
Iron  
(µg/dL) 
117.5 30 349 
Table 4: Type of Antiviral Response (n= 82) 
Non Responders (NR) /Relapsers (RR)  21 (25.6%) / 8 (9.8%)  
Sustained viral Response (SVR)  53 (64.6%)  
 HFE polymorphisms frequency 
HFE_H63D and C282Y genotype frequency 
in the CHC studied population is 
summarized in Table 5. 
 
 HFE polymorphisms and the type 
response to antiviral therapy 
No significant difference was found 
comparing HFE polymorphisms and the 
type of antiviral response. 
 
 
Table 5. HFE_H63D and C282Y genotype frequency in the CHC studied 
population (N= 183) 
HFE_H63D N (%)  HFE_C282Y N (%) 
HH 121 (66.1) CC 173 (94.5) 
HD 54 (29.5) CY 10 (5.5) 
DD 8 (4.4) YY 0 
 HFE polymorphisms and clinical or 
histological data: 
 
•    HFE_H63D: regarding all the 
clinical and histological data, we 
observed a decrease in the degree of 
inflammation (Table 6) and in 
tGSH/GSSG ratio, and an increase in 
total cholesterol (Table7; Fig. 1 and 2) 
in CHC patients presenting the H63D 
mutant allele (HD+DD) comparing to 
HH individuals. 
 
Table 7. Association of HFE_H63D with Total Cholesterol and tGSH/GSSG Ratio  
Clinical parameters 
(normal distribution) 
HFE_H63D Mean 
Std 
Deviation 
N p Value 
Total Cholesterol 
(mmol/L) 
HH 4.289 0.984 108 
0.042 
HD+DD 4.689 1.255 57 
tGSH/GSSG Ratio 
HH 6.87 2.15 31 
0.006 
HD+DD 4.81 2.08 14 
Table 6. Association between HFE_H63D and Inflammation  
Parameter Stage 
H63D (HH) 
N (%) 
H63D (HD+DD) 
N (%) 
p Value 
Inflammation 
(grading) 
Mild (1-3) 10 (13.5) 15 (39.5) 
0.004 
Moderate (4-6) 64 (86.5) 23 (60.5) 
•    HFE_C282Y: Our study revealed that heterozygous C282Y had lower Total Cholesterol 
(p<0.0001) and higher serum Iron and Transferrin Saturation levels (p<0.0001 and 0.006, 
respectively); (Table 8; Fig. 3-5). 
Table 8: Association of HFE_C282Y with Total Cholesterol, Transferrin saturation and serum Iron level   
Clinical parameters 
(normal distribution) 
HFE_C282Y Mean Std Deviation N p Value 
Total Cholesterol (mmol/L) 
CC 4.48 1.11 156 
<0.0001 
CY 3.72 0.38 9 
Transferrin saturation (%) 
CC 43.32 20.50 86 
0.006 
CY 63.18 14.35 5 
Clinical parameters 
(non normal distribution) 
HFE_C282Y Median [min-max] N p Value 
Iron (µg/dL) 
CC 115 [30-349] 111 
0.038 
CY 161 [99-220) 7 
Fig. 1 Fig. 2 
 Association between Total Cholesterol, Iron and Transferrin Saturation and histological data or type 
of response to antiviral therapy (Table 9) 
 
• Total Cholesterol was found to be increased in patients with less necroinflammation and steatosis 
(p=0.023 and p=0.046), respectively.  
•  Higher serum iron levels are observed in patients with higher fibrosis stages (moderate and intense); 
(p=0.042).  
Fig. 3 Fig. 5 Fig. 4 
Table 9. Association between Total Cholesterol and Iron and Histological data 
Clinical parameters 
(normal distribution) 
Histological data Mean Std Deviation N p Value 
Total Cholesterol (mmol/L) 
Inflamation 
(grading) 
Mild (1-3) 4.92 1.16 23 
0.023 
Moderate (4-6) 4.36 0.98 77 
Steatosis Grade 
Mild (1+2) 4.55 0.97 47 
0.046 
Moderate and severe(3+4) 3.70 0.89 18 
Clinical parameters 
(non normal distribution) 
Histological data Median [min-max] N p Value 
Iron (µg/dL) 
Fibrosis 
(staging) 
F1/2 114 [38-211] 52 
0.042 
F3/4 139 [30-316] 17 
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   In this CHC population, the C282Y polymorphism was associated to higher serum 
iron levels. This biochemical phenotype was in turn observed in patients with higher 
fibrosis stages. 
   C282Y was also found associated with lower total cholesterol, which in turn was 
observed in patients with more severe liver inflammatory and steatosis grade.    
   On the other hand, the H63D polymorphism was found associated with higher 
total cholesterol levels and less necroinflammation. In addition, it was also associated 
with a decreased antioxidant potential (tGSH/GSSG ratio).   
   These data suggest a relevant role of HFE_H63D and C282Y polymorphisms in 
CHC progression (liver fibrosis, inflammation and steatosis).  
   We did not find association between these two HFE polymorphisms and the type 
of response to the anti-viral therapy (Pegynterferon + Ribavirin). 
